Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 2.92B 3.33B 2.69B 2.5B 4.74B 318B 4.81B 32.2B 12.53B 156B 12.52B 12.25B 541B P/E 2026 *
21.8x
P/E 2027 * 16.4x
Enterprise Value 2.89B 3.3B 2.66B 2.47B 4.7B 315B 4.76B 31.89B 12.41B 155B 12.4B 12.13B 536B EV / Sales 2026 *
3.74x
EV / Sales 2027 * 3.16x
Free-Float
31.63%
Yield 2026 *
1.71%
Yield 2027 * 1.97%
1 day+0.35%
1 week-2.56%
Current month-1.30%
1 month-2.89%
3 months-30.91%
6 months-12.02%
Current year-10.08%
1 week 56
Extreme 56
58.85
1 month 56
Extreme 56
59.7
Current year 56
Extreme 56
86.7
1 year 51.65
Extreme 51.65
86.7
3 years 37.96
Extreme 37.96
94.8
5 years 35.2
Extreme 35.2
94.8
10 years 10.8
Extreme 10.8
94.8
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Date Insider Type Main position Quantity % Market Cap.
23/06/23Buy

Director

1,000 0.0019%
13/04/22
Norbel Inversiones SL
SellCompany 560,690 1.0000%
15/03/22
Norbel Inversiones SL
SellCompany 2,803,448 5.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+0.35%-2.56%+1.60%+39.27% 3.33B
-1.14%-2.43%+55.27%+159.07% 1,082B
-1.41%+0.32%+67.02%+60.48% 633B
-2.42%+0.18%+35.78%+85.62% 461B
-2.79%+1.37%+31.00%+23.05% 338B
-2.46%-1.52%+36.42%+32.77% 299B
-2.20%-0.93%+27.50%+40.62% 291B
-1.77%+0.99%-28.85%-41.41% 222B
-2.06%+1.63%+25.09%+64.34% 202B
-1.26%+2.60%+15.95%+70.00% 163B
Average -1.65%+3.72%+26.68%+53.38% 369.57B
Weighted average by Cap. -1.65%+5.42%+40.44%+79.76%

Financials

2026 *2027 *
Net sales 774M 884M 713M 662M 1.26B 84.3B 1.27B 8.53B 3.32B 41.38B 3.32B 3.25B 143B 898M 1.03B 827M 768M 1.46B 97.83B 1.48B 9.9B 3.85B 48.02B 3.85B 3.77B 166B
Net income 133M 152M 122M 114M 216M 14.48B 219M 1.47B 571M 7.11B 570M 558M 24.65B 178M 203M 164M 152M 288M 19.34B 292M 1.96B 762M 9.5B 762M 745M 32.92B
Net Debt -27.87M -31.82M -25.67M -23.83M -45.25M -3.04B -45.86M -307M -120M -1.49B -120M -117M -5.17B -85.9M -98.08M -79.12M -73.44M -139M -9.36B -141M -947M -369M -4.59B -368M -360M -15.92B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
1,998
Date Price Change Volume
06/07/26 57.10 +0.35% 254,302
03/07/26 €56.90 -0.87% 226,428
02/07/26 €57.40 -0.17% 107,292
01/07/26 €57.50 -0.61% 74,835
30/06/26 €57.85 -1.45% 129,596
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
56.90EUR
Average target price
75.38EUR
Spread / Average Target
+32.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ROVI Stock